Exelixis, inc. EXEL.US 總覽分析
)EXEL 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
EXEL 近期報酬表現
-0.66%
Exelixis, inc.
1.86%
同產業平均
0.63%
S&P500
與 EXEL 同產業的標的表現
- EPRX Eupraxia pharmaceuticals inc價值 -趨勢 4 分波段 2 分籌碼 -股利 1 分查看更多
EXEL 公司資訊
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.